华兰生物
(002007)
| 流通市值：226.86亿 | | | 总市值：263.52亿 |
| 流通股本：15.73亿 | | | 总股本：18.27亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 762,111,441.69 | 4,595,017,702.01 | 3,378,886,377.05 | 1,798,197,926.21 |
| 营业收入 | 762,111,441.69 | 4,595,017,702.01 | 3,378,886,377.05 | 1,798,197,926.21 |
| 二、营业总成本 | 545,394,537.65 | 3,373,662,053.19 | 2,486,370,142.96 | 1,310,025,664.46 |
| 营业成本 | 379,626,095.69 | 1,951,537,637.59 | 1,429,887,222.67 | 852,704,797.25 |
| 税金及附加 | 12,962,278.49 | 41,463,397.65 | 29,569,149.05 | 18,377,625.38 |
| 销售费用 | 42,416,454.79 | 818,067,517.05 | 606,912,297.65 | 151,069,877.18 |
| 管理费用 | 51,856,532.47 | 224,672,887.88 | 186,141,562.82 | 126,062,364.68 |
| 研发费用 | 59,505,137.95 | 337,463,026.21 | 234,642,551.42 | 161,354,978.4 |
| 财务费用 | -971,961.74 | 457,586.81 | -782,640.65 | 456,021.57 |
| 其中:利息费用 | 95,517.78 | 10,242,183.52 | 6,387,108.39 | 5,494,257.26 |
| 其中:利息收入 | 1,173,740.52 | 10,091,199.6 | 7,372,471.51 | 4,955,816.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,066,763.04 | 15,171,586.8 | 17,337,962.29 | 12,504,878.82 |
| 加:投资收益 | 33,139,690.31 | 62,497,631.37 | 85,482,183.32 | 78,427,996.02 |
| 资产处置收益 | -321,301.63 | 2,891,234.85 | 500,095.9 | -21,450.45 |
| 资产减值损失(新) | 200,043.72 | -58,207,765.52 | 12,277,453.7 | 12,277,453.7 |
| 信用减值损失(新) | 41,591,811.05 | -34,060,814.15 | -12,607,418.2 | 34,568,937.15 |
| 其他收益 | 3,164,489.81 | 18,894,571.04 | 12,593,010.37 | 9,173,135.8 |
| 四、营业利润 | 298,558,400.34 | 1,228,542,093.21 | 1,008,099,521.47 | 635,103,212.79 |
| 加:营业外收入 | 495,491.44 | 463,766.9 | 423,838.59 | 220,548.37 |
| 减:营业外支出 | 9,553,514.42 | 55,657,495.8 | 36,109,120.64 | 23,879,654.13 |
| 五、利润总额 | 289,500,377.36 | 1,173,348,364.31 | 972,414,239.42 | 611,444,107.03 |
| 减:所得税费用 | 46,905,881.15 | 173,355,516.73 | 144,713,247.09 | 88,752,716.99 |
| 六、净利润 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 | 522,691,390.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 | 522,691,390.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 230,349,018.41 | 940,400,665.87 | 784,423,022.36 | 515,859,492.79 |
| 少数股东损益 | 12,245,477.8 | 59,592,181.71 | 43,277,969.97 | 6,831,897.25 |
| 扣除非经常损益后的净利润 | 226,806,935.99 | 936,794,228.45 | 742,438,601.83 | 484,042,073.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.13 | 0.52 | 0.43 | 0.28 |
| (二)稀释每股收益 | 0.13 | 0.52 | 0.43 | 0.28 |
| 九、综合收益总额 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 | 522,691,390.04 |
| 归属于母公司股东的综合收益总额 | 230,349,018.41 | 940,400,665.87 | 784,423,022.36 | 515,859,492.79 |
| 归属于少数股东的综合收益总额 | 12,245,477.8 | 59,592,181.71 | 43,277,969.97 | 6,831,897.25 |
| 公告日期 | 2026-04-27 | 2026-03-28 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |